0
Abstract: Slide Presentations |

COMPARISON OF THE BACTERIAL ETIOLOGY OF EARLY-ONSET VENTILATOR-ASSOCIATED PNEUMONIA AND LATE-ONSET VENTILATOR-ASSOCIATED PNEUMONIA IN PATIENTS ENROLLED IN 2 LARGE CLINICAL STUDIES FREE TO VIEW

Marcos I. Restrepo, MD*; Janet Peterson, PhD; Zhihai Qin, PhD; Alan C. Fisher, DrPH; Susan C. Nicholson, MD
Author and Funding Information

University of Texas Health Science Center San Antonio (U.T.H.S.C.S.A.), VERDICT, San Antonio, TX


Chest


Chest. 2009;136(4_MeetingAbstracts):37S. doi:10.1378/chest.136.4_MeetingAbstracts.37S-g
Text Size: A A A
Published online

Abstract

PURPOSE:  To assess potential differences in bacterial etiology of subjects with early-onset vs. late-onset ventilator associated pneumonia (VAP).

METHODS:  Subjects enrolled in 2004–2006 in 2 clinical studies of doripenem vs. imipenem or piperacillin/tazobactam with a diagnosis of VAP (N=500) were included in the analysis. Subjects were classified by ventilator status [early-onset VAP (<5 days of ventilation) or late-onset VAP (≥5 days of ventilation)]. Baseline demographics and bacterial etiology were analyzed by VAP status.

RESULTS:  Late-onset VAP subjects had higher APACHE II scores [mean 16.6 vs. 15.5 (p=0.008)].There were no significant differences in CPIS, gender, age, or presence of bacteremia between groups. A total of 496 subjects had a baseline pathogen and 50% of subjects in each group had ≥2 pathogens. With the exception of S aureus, which was common in early-onset VAP, pathogens, including potentially MDR, isolated from early vs. late-onset VAP was not significantly different between groups. A baumannii or P aeruginosa resistant to any study drug was observed in 8 early vs. 10 late onset VAP subjects.

CONCLUSION:  There were no significant differences in the prevalence of MDR pathogens associated with early or late-onset VAP.

CLINICAL IMPLICATIONS:  VAP is classified as early-onset or late-onset, in part, to identify subjects at risk for infection with resistant pathogens. Empiric therapy for early-onset VAP should also include agents likely to be effective for potential MDR pathogens. Further prospective studies should evaluate microbiology trends in patients with VAP.

DISCLOSURE:  Marcos Restrepo, Grant monies (from sources other than industry) Dr. Restrepo is supported by a Department of Veteran Affairs Veterans Integrated Service Network 17 new faculty grant and a CTSA Award Number (KL2 RR025766).; Employee Drs Peterson, Qin, Fisher, and Nicholson are full time employees of Ortho-McNeil Janssen Scientific Affairs, LLC; Consultant fee, speaker bureau, advisory committee, etc. Dr. Restrepo has served on advisory boards for Ortho-McNeil-Janssen and Johnson & Johnson. Dr. Restrepo has also served on speakers bureaus for Ortho-McNeil-Janssen and Johnson & Johnson.; Product/procedure/technique that is considered research and is NOT yet approved for any purpose. This abstract reviews the bacterial etiology of early versus late-onset ventilator-associated pneumonia (VAP) from 2 large clinical trials of doripenem in the treatment of subjects with nosocomial pneumonia (NP) and/or VAP. The data is from these trials, however, this specific analysis/abstract solely reports on the baseline bacterial etiology of subjects diagnosed with either early or late-onset VAP enrolled in these studies. It does not discuss the use of doripenem in the treatment of either NP or VAP. Doripenem is currently not approved in the US for the treatment of NP or VAP. Doripenem is approved in the US for the treatment of complicated intra-abdominal infections and complicated urinary tract infections

Tuesday, November 3, 2009

10:30 AM - 12:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543